Table 2.
Model A: No medications included | Model B: Corticosteroid included | Model C: AZA/MTX included | ||||
---|---|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
Sex (male referent) | 0.14 (0.04 to 0.58) | 0.006 | 0.10 (0.01 to 1.27) | 0.076 | 0.09 (0.02 to 0.52) | 0.007 |
Age at diagnosis (years) | 1.07 (1.04 to 1.11) | 0.000 | 1.06 (1.01 to 1.12) | 0.018 | 1.11 (1.06 to 1.16) | 0.000 |
Race (white referent) | ||||||
Black | 3.94 (1.48 to 10.46) | 0.006 | 1.5 (0.3 to 7.4) | 0.61 | 9.5 (2.42 to 37.09) | 0.001 |
Other or unknown | 2.03 (0.66 to 6.29) | 0.22 | 0.86 (0.19 to 4.0) | 0.85 | 5.6 (1.3 to 24.3) | 0.021 |
Diagnosis (PM referent) | 0.78 (0.24 to 2.54) | 0.681 | 1.14 (0.26 to 5.1) | 0.86 | 0.30 (0.1 to 1.5) | 0.141 |
Sex-diagnosis interaction | 6.41 (1.22 to 33.7) | 0.028 | 12.5 (0.65 to 241.5) | 0.10 | 15.7 (1.9 to 128.0) | 0.010 |
IV corticosteroid (vs oral) | - | - | 5.6 (1.6 to 20.3)b | 0.008 | - | - |
MTX (vs AZA) | - | - | - | - | 0.96 (0.3 to 2.8) | 0.938 |
aAZA = azathioprine; CK = creatine kinase; IIM = idiopathic inflammatory myopathy; ILD = interstitial lung disease; IV = intravenous; MTX = methotrexate; PM = polymyositis. bSteroid association was restricted to the white subset of the study population when stratified models were used. Inclusion of initial CK level, comorbid ILD or cancer (ever or within 3 years of IIM diagnosis) in additional models did not substantively affect results.